VSTM
HEALTHCAREVerastem Inc
AI Insight
What's Moving VSTM Today?
No stock-specific AI insight has been generated for VSTM yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$3.55$11.25
$4.21
Fundamentals
Market Cap$373M
P/E Ratio—
EPS$-2.52
Dividend Yield—
Dividend / Share—
ROE-786.0%
Profit Margin—
Debt / Equity—
Trading
Volume2.6M
Avg Volume (10D)—
Shares Outstanding87.9M
VSTM News
23 articles- Verastem Says VS-7375 Trial Data Shows Anti-Tumor Activity in Advanced Solid TumorsYahoo Finance·Jun 23, 2026
- VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid TumorsYahoo Finance·Jun 23, 2026
- Verastem (NASDAQ: VSTM) insider sale notice — 20,871 shares proposedStock Titan·Jun 23, 2026
- Verastem (Nasdaq: VSTM) reports RAMP 205 pancreatic data and starts KRAS G12D trialStock Titan·Jun 17, 2026
- Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic CancerYahoo Finance·Jun 17, 2026
- Verastem Oncology Doses First Patient in TARGET-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Pancreatic CancerYahoo Finance·Jun 16, 2026
- Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical ProgramYahoo Finance·Jun 15, 2026
- VSTM Stock Climbs After-Hours As FDA Grants Fast Track To Lung Cancer Drug — Retail Eyes The Next KeytrudaStocktwits·Jun 4, 2026
- Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerYahoo Finance·Jun 3, 2026
- Verastem (VSTM) director awarded 36,000 RSUs vesting through 2027Stock Titan·May 27, 2026
- Verastem Oncology Appoints Michael P. Bailey to its Board of DirectorsYahoo Finance·May 26, 2026
- Verastem (VSTM) Loses 34.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerYahoo Finance·May 18, 2026
- Verastem Oncology to Present at Upcoming Investor ConferencesYahoo Finance·May 12, 2026
- Verastem, Inc. (NASDAQ:VSTM) Just Released Its First-Quarter Earnings: Here's What Analysts ThinkYahoo Finance·May 11, 2026
- Verastem Q1 Earnings Call HighlightsMarketbeat·May 9, 2026
- Verastem (VSTM) Q1 2026 Earnings TranscriptMotley Fool·May 8, 2026
- On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian CancerYahoo Finance·May 8, 2026
- Verastem (VSTM) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 7, 2026
- Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business UpdatesBusiness Wire·May 7, 2026
- Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian CancerYahoo Finance·Apr 30, 2026
- Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026Yahoo Finance·Apr 23, 2026
- Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women’s CancersYahoo Finance·Apr 10, 2026
- Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Apr 2, 2026
All 23 articles loaded
Price Data
Open$4.19
Previous Close$4.25
Day High$4.41
Day Low$4.15
52 Week High$11.25
52 Week Low$3.55
52-Week Range
$3.55$11.25
$4.21
Fundamentals
Market Cap$373M
P/E Ratio—
EPS$-2.52
Dividend Yield—
Dividend / Share—
ROE-786.0%
Profit Margin—
Debt / Equity—
Trading
Volume2.6M
Avg Volume (10D)—
Shares Outstanding87.9M
About Verastem Inc
Verastem, Inc., a developing-stage biopharmaceutical company focused on developing and commercializing life-enhancing drugs for cancer patients. The company is headquartered in Needham, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—